ACR 2026 Annual Meeting CME Sessions

3 - 5pm / Radiation Oncology Session

Therapeutic Radiopharmaceuticals: Where Specialties Combine to Bring Novel Cancer Interventions
While radiopharmaceutical therapy has become one of the latest exciting buzzwords due to its ability to directly target tumors, there is much to be understood about the current standard of practice, what is needed to deliver these agents successfully, and how to work with various specialties at your practice to do so. Hear perspectives from radiation oncology, radiation physics, radiology, and nuclear medicine to help remove some of these hurdles so you can feel prepared to implement radiopharmaceutical therapy at your practice.

Moderators:

• Arya Amini, MD
• Steven E. Finkelstein, MD, DABR, FACRO

Speakers:

• Celeste Winters, PhD – Clinical RPT Dosimetry: Motivation, Methods, and Implementation
• Neil Taunk, MD – PSMA Theranostics: Moving Earlier, Optimizing Patient Selection
• Vikas Prasad, MD, PhD – Imaging as Gatekeeper for Theranostics

1:45 - 2:45pm / Moreton Lecture

Finding a Seat at the Health System Table: Radiology in a Time of Transformation
Step inside the minds of C-suite leaders with Richard P. Shannon, MD, Senior Vice President and Chief Medical Officer, DUHS and Chief Quality Officer, Duke Health, to understand their perspective on health care transformation. Learn how health system leaders see headwinds and where they find common ground with radiologists. This session will equip radiologists with a constructive approach to find their place in the health system hierarchy in a time of transformation.

Speaker: Richard P. Shannon, MD

4 - 5pm / Government Relations Session

Advocacy in Action: Navigating Legislative and Policy Challenges in Radiology
This session will provide an in-depth look at how radiology professionals and ACR chapters can effectively advocate for policies that protect patients and the practice of radiology. Using real-world examples, we will explore the lifecycle of advocacy campaigns—from identifying an issue to influencing policy change—while highlighting practical strategies and tools for success.

Moderator: Amy K. Patel, MD

Speakers:

• Dillon Harp
• Leah C. Davis, DO
• Rebecca Spangler
• Neil C. Davey, MD, MB, FACR, ChB

8:45 - 10:15am / Economics Forum

Economics Forum: Current and Future States of Advocacy and Economics
The year’s Economics Forum will cover advocacy today and tomorrow; updates from the commercial payer world; a CPT and RUC update; practice expense input changes; and activities of the AI Economics Committee.

Moderator: Gregory Nicola, MD, FACR

Speakers:

• Bobby Mukkamala, MD
• Lauren Nicola, MD
• Cindy Yuan, MD, PhD
• Michael Booker, MD
• Frankie J. Rybicki, III, MD, PhD, FACR

10:45am – Noon / Open Microphone

Open Microphone Session: Emerging Trends in Radiology Workforce and Coverage
Join this interactive open microphone session for a discussion on the evolving radiology workforce landscape. Attendees are invited to share experiences, challenges, and innovative approaches shaping how radiology services are staffed and delivered today.

Topics may include, but are not limited to, the growing role of independent contractors, radiology group alliances, cross-coverage and internal and external moonlighting arrangements, and the integration of part-time and semi-retired radiologists. Whether you’re navigating staffing shortages, exploring flexible work models, or planning for long-term workforce sustainability, this session provides a collaborative forum to learn from peers across the field.

Moderators:

• Daniel A. Rodgers, MD
• David T. Boyd, MD, MBA, FACR

The American College of Radiology (ACR) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by ACR are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by ACR in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by ACR to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the ACR.

The following planners and managers have no relevant financial relationships with ineligible companies:

Terence T. Sio, MD, MS; Randa Tao, MD; Emile Gogineni, DO; Steve Marcus; Eric Rubin, MD, FACR; Trina Behbahani; Melody Ballesteros; Ted Burnes; Gregory Nicola, MD, FACR; Angela Kim; Daniel A. Rodgers, MD; David T. Boyd, MD, MBA, FACR; Lisa Gunderman; Andrea Alsup

The following planners and managers have the following relevant financial relationships with ineligible companies:

Arya Amini, MD — Consulting Fee: AstraZeneca
Amy K. Patel, MD — Consulting Fee: Hologic, Beekly Medical, SuperSonic Imagine

The following moderators have no relevant financial relationships with ineligible companies:

Gregory Nicola, MD, FACR; Daniel A. Rodgers, MD; David T. Boyd, MD, MBA, FACR

The following moderators have the following relevant financial relationships with ineligible companies:

Arya Amini, MD — Consulting Fee: AstraZeneca

Steven E. Finkelstein, MD, DABR, FACRO — Stock Options: ImmunityBio, Histosonics; Consulting Fee: Astellas, Bayer, Blue Earth, ImmunityBio, Jansen, Lantheus, Pfizer, Progenics; Honoraria: Astellas, Bayer, Blue Earth, ImmunityBio, Jansen, Lantheus, Pfizer, Progenics; Contracted Research: Bayer, Pfizer, Astellas Pharma, Merck, AstraZeneca, Advantagene, Dendreon, Janssen Oncology, InVitae, Candel Therapeutics, CG Oncology, ImmunityBio, Novartis

Amy K. Patel, MD — Consulting Fee: Hologic, Beekly Medical, SuperSonic Imagine

The following faculty members have no relevant financial relationships with ineligible companies:

Bobby Mukkamala, MD; Michael Booker, MD; Frank J. Rybicki, III, MD, PhD, FACR; Celeste Winters, PhD; Dillon Harp; Leah C. Davis, DO; Rebecca Spangler; Neil C. Davey, MD, MB, FACR, ChB; Richard P. Shannon, MD

The following faculty members (speakers and content developers) have the following relevant financial relationships with ineligible companies:

Lauren Nicola, MD — Stock Options Holder: Medimaps, Bayer

Cindy Yuan, MD, PhD — Stock Shareholder: Lantheus; Contracted Research: GE Healthcare, Sofie, Radionetics, previously RayzeBio

Neil Taunk, MD — Consulting Fee: Eli Lilly, GE Healthcare, Novartis; Contracted Research: Novartis; Honoraria: Eli Lilly, GE Healthcare, Novartis

Vikas Prasad, MD, PhD — Consulting Fee: Curium, Lilly, Cellectar, ITM; Honoraria: Siemens